SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...

-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH -- Morag Griffin, MBChB, FRCPath, Consultant in Haematology of St.

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, severe, and potentially life-threatening condition. Treatments targeting the complement pathway have revolutionized its management but have ...

Please provide your email address to receive an email when new articles are posted on . Zaltenibart is the most proximal inhibitor of the alternative pathway. Phase 3 clinical trials for the inhibitor ...

Dr De Castro provides an overview of IV versus oral therapies for patients with PNH. Carlos M. De Castro, MD: If you look at complements, they’re activated in 3 ways. There’s the classical pathway, an ...

The European Medicines Agency (EMA) has granted a marketing authorization to Novartis Europharm for Fabhalta (iptacopan) for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have ...